Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Emerging therapies in pancreas cancer.

Literature DB >> 22811835

Emerging therapies in pancreas cancer.

Abstract

Pancreas cancer has a grave prognosis and treatment options remain limited despite advancement in anti-cancer chemotherapeutics. This review provides an overview of the emerging therapies for pancreas cancer, focusing on novel signal transduction inhibitors (insulin-like growth factor receptor, hedgehog/Smo, PI3k/Akt/mTOR) and cytotoxics (nab-paclitaxel) that are currently in clinical development. Despite the impact molecularly targeted agents have on other tumor types, their application without cytotoxics in pancreas cancer remains limited. In addition, recent report of the superiority of an intensive cytotoxic regimen using fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) over gemcitabine reminded us of the importance of cytotoxics in this disease. As such, the future of pancreas cancer therapy may be combination regimens consisting of cytotoxics and molecularly targeted agents.

Entities: Chemical Disease Gene

Keywords: Pancreas cancer; chemotherapy; target therapy

Year: 2011 PMID： 22811835 PMCID： PMC3397600 DOI： 10.3978/j.issn.2078-6891.2011.002

Source DB: PubMed Journal: J Gastrointest Oncol ISSN： 2078-6891

72 in total

1. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).

Authors: T Suhara; T Mano; B E Oliveira; K Walsh
Journal: Circ Res Date: 2001-07-06 Impact factor: 17.367

2. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors: J Brognard; A S Clark; Y Ni; P A Dennis
Journal: Cancer Res Date: 2001-05-15 Impact factor: 12.701

3. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors: Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal: Nat Med Date: 2002-02 Impact factor: 53.440

4. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Authors: Nuhad K Ibrahim; Neil Desai; Sewa Legha; Patrick Soon-Shiong; Richard L Theriault; Edgardo Rivera; Bita Esmaeli; Sigrid E Ring; Agop Bedikian; Gabriel N Hortobagyi; Julie A Ellerhorst
Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531

5. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.

Authors: Nuhad K Ibrahim; Brian Samuels; Ray Page; Dinesh Doval; Kirtikumar M Patel; S C Rao; Madhavan Krishnan Nair; Paul Bhar; Neil Desai; Gabriel N Hortobagyi
Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544

6. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.

Authors: Minoru Tomizawa; Fuminobu Shinozaki; Takao Sugiyama; Shigenori Yamamoto; Makoto Sueishi; Takanobu Yoshida
Journal: World J Gastroenterol Date: 2010-04-21 Impact factor: 5.742

7. Functional roles of Akt signaling in mouse skin tumorigenesis.

Authors: Carmen Segrelles; Sergio Ruiz; Paloma Perez; Cristina Murga; Mirentxu Santos; Irina V Budunova; Jesús Martínez; Fernando Larcher; Thomas J Slaga; J Silvio Gutkind; Jose L Jorcano; Jesús M Paramio
Journal: Oncogene Date: 2002-01-03 Impact factor: 9.867

8. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors: Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal: Sci Transl Med Date: 2010-09-29 Impact factor: 17.956

9. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Authors: Floriana Morgillo; Woo-Young Kim; Edward S Kim; Fortunato Ciardiello; Waun Ki Hong; Ho-Young Lee
Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531

Review 10. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

Authors: Courtney A Granville; Regan M Memmott; Joell J Gills; Phillip A Dennis
Journal: Clin Cancer Res Date: 2006-02-01 Impact factor: 12.531

5 in total

Emerging therapies in pancreas cancer.

1. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP).

2. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

3. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

4. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

5. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.

6. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer.

7. Functional roles of Akt signaling in mouse skin tumorigenesis.

8. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

9. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.

Review 10. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

1. JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells.

Review 2. In vivo delivery of miRNAs for cancer therapy: challenges and strategies.

3. Pancreatic cancer: current standards, research updates and future directions.

4. The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines.

5. Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways.